Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale

Rhea-AI Filing Summary

Dermata Therapeutics director Kathleen D. Scott reported a small open-market sale of common stock. She sold 11 shares of Dermata Therapeutics, Inc. common stock in an open-market transaction at a price of $1.1901 per share. After this sale, she held no shares directly but reported indirect ownership of 1 share held by the Scott 2008 Trust Dated 3/28/08.

Insider Trade Summary

Net Seller: 11 shares

Net Sell 2 txns

Insider Scott Kathleen D.

Role Director

Sold 11 shs ($13.09)

Type	Security	Shares	Price	Value
Sale	Common Stock	11	$1.1901	$13.09
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct); Common Stock — 1 shares (Indirect, By Scott 2008 Trust Dated 3/28/08)

Key Figures

Shares sold: 11 shares Sale price: $1.1901 per share Direct holdings after transaction: 0 shares +2 more

5 metrics

Shares sold 11 shares Open-market sale of common stock

Sale price $1.1901 per share Price for the 11 shares sold

Direct holdings after transaction 0 shares Common stock directly owned post-sale

Indirect holdings after transaction 1 share Held by Scott 2008 Trust Dated 3/28/08

Net shares sold 11 shares Net buy/sell shares for this Form 4

Key Terms

open-market sale, indirect ownership, Scott 2008 Trust Dated 3/28/08

3 terms

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"ownership_type": "indirect""

Scott 2008 Trust Dated 3/28/08 financial

"nature_of_ownership": "By Scott 2008 Trust Dated 3/28/08""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 04:16 PM Accepted by SEC EDGAR 06/16/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report for Kathleen D. Scott?

Dermata Therapeutics reported that director Kathleen D. Scott sold 11 shares of common stock in an open-market transaction. The sale was recorded at a price of $1.1901 per share, according to the Form 4 insider trading report.

At what price did Kathleen D. Scott sell Dermata Therapeutics (DRMA) shares?

Kathleen D. Scott sold Dermata Therapeutics common stock at $1.1901 per share. The Form 4 filing lists this as the transaction price for the 11 shares sold in an open-market or private transaction on the reported date.

How many Dermata Therapeutics (DRMA) shares did Kathleen D. Scott sell and what remains?

Kathleen D. Scott sold 11 shares of Dermata Therapeutics common stock, leaving her with zero directly owned shares. The filing also shows she indirectly holds 1 share through the Scott 2008 Trust Dated 3/28/08.

Does Kathleen D. Scott still own Dermata Therapeutics (DRMA) shares after this Form 4 transaction?

After the reported sale, Kathleen D. Scott holds no Dermata Therapeutics shares directly. However, the Form 4 indicates indirect ownership of 1 share of common stock through the Scott 2008 Trust Dated 3/28/08.

What type of insider transaction was reported for Dermata Therapeutics (DRMA) on this Form 4?

The Form 4 shows an open-market sale of Dermata Therapeutics common stock by director Kathleen D. Scott. The transaction used code "S," indicating a sale in an open-market or private transaction under SEC reporting rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scott Kathleen D.

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD., #322

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S		11	D	$1.1901	0	D
Common Stock								1	I	By Scott 2008 Trust Dated 3/28/08

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gerald T. Proehl, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)